インデックス付き
- 学術雑誌データベース
- Jゲートを開く
- Genamics JournalSeek
- ジャーナル目次
- 研究聖書
- ウルリッヒの定期刊行物ディレクトリ
- 電子ジャーナルライブラリ
- レフシーク
- ハムダード大学
- エブスコ アリゾナ州
- OCLC-WorldCat
- 学者の舵取り
- SWBオンラインカタログ
- 仮想生物学図書館 (vifabio)
- パブロン
- ミアル
- ジュネーブ医学教育研究財団
- ユーロパブ
- Google スカラー
このページをシェアする
ジャーナルチラシ
概要
Leveraging Lymphoblastoid Cell Lines for Drug Response Modeling
Alison A Motsinger-Reif1,2 and Daniel M Rotroff1,2*
Lymphoblastoid cell lines (LCL) are becoming popular tools for modeling drug response. LCLs, and other in vitro assays, offer the ability to test many drugs, doses, and biological samples relatively quickly and inexpensively. In addition, a unique advantage to LCLs is that they are available from a large cohort of individuals, providing the capability to test for genetic variability on a scale not readily available in other in vitro systems. Since oftentimes the genotype data is publically available, the experimental costs can be limited to the cost of the drug response phenotyping. Here we describe several advantages and limitations of LCLs. In addition we review several important aspects of LCL experimental design and statistical analysis. Lastly, we present an example of LCLs being successfully used to identify candidate single nucleotide polymorphisms and genes for variability in response to a chemotherapeutic used to treat chronic myeloid leukemia.